George Gilbert Head, M.D.
Cognitive Clinical Trials Research
8901 E. Pima Center Parkway, Suite 115
Scottsdale, AZ 85258

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Family Medicine at Legacy
17241 Oak Drive
Omaha, NE 68130

EDUCATION:

1976 – 1980 Doctorate of Medicine
University of Iowa, Iowa City, IA

1972 – 1976 Bachelor of Arts
Simpson College, Indianola, IA

RESIDENCY:

1980 - 1983 Family Practice Residency
Cedar Rapids Medical Education Program, Cedar Rapids, IA

LICENSURE:

1983 – Present	Nebraska Medical License (16328)
1983 – Present	American Board of Family Medicine

MEMBERSHIPS:

1983 – Present	American Academy of Family Physicians
1983 – Present	Nebraska Academy of Family Physicians
1983 – Present	Nebraska Medical Association
1983 – Present	Metro Omaha Medical Society
1997 – Present	UniNet Physician/Hospital Organization
2014 – Present	MIPPA (Midwest Independent Physicians Practice Association)

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2019 – Present
Cognitive Clinical Trials Research, Omaha, NE

Affiliate, 2014 – Present
MDVIP Personalized Health Care, Omaha, NE

Founder/President, 1983 – Present
Family Medicine Associates Millard/Gretna, P.C., Omaha, NE

INVESTIGATOR EXPERIENCE:

Acne • Asthma • Benign Prostatic Hyperplasia • Clostridium difficile • COPD • Herpes Labialis
Hypertension • Hypogonadism • Men's Health • Migraine • Nocturia • Overactive Bladder
Pediatric • Psoriasis • Type 2 Diabetes • Women's Health

INVESTIGATOR EXPERIENCE:

Acne

A Randomized, Double-blind, Vehicle-controlled, Efficacy and Safety Study of XXX Gel in Subjects with Acne Vulgaris

An Open-Label Study Assessing Long-Term Safety of XXX Gel in Subjects with Acne Vulgaris

Asthma

An 8 week, Randomized, Double-blind, Placebo and Active-controlled, Parallel-group, Dose Ranging Study to Evaluate the Efficacy and Safety of 3 Doses of XXX in Asthmatic Subjects

A Randomized, Double-blind, Parallel-group, Multi-center 24-week Study Comparing the Efficacy and Safety of Three Doses of XXX to Placebo and Open-label Spiriva Respimat in Subjects with Persistent Asthma

Clostridium difficile

A Multicenter, Double-blind, Parallel-arm, Placebo-controlled, Phase II Study of the Efficacy, Safety and Tolerability of Oral Full-Spectrum XXX in Subjects with Recurrence of Clostridium Difficile Infection

INVESTIGATOR EXPERIENCE (*continued*):

COPD

A 6 week, Randomized, Double-blind, Placebo and Active-controlled, Parallel-group, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of XXX in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

A 12 week, Open-Label Study to Evaluate the Relationship Between use of Albuterol eMDPI an Inhaled Short-acting Beta Agonist Rescue Agent with an eModule, and Exacerbations in Patients (40 years of age or older) with Chronic Obstructive Pulmonary Disease (COPD)

Diabetes

A Real-world, Point-of-care, Randomized, Parallel Group, Open, 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients with Type 2 Diabetes Mellitus

A 52 week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of XXX compared to XXX or Placebo Added to Metformin in Patients with Type 2 Diabetes who have inadequate Glycemix control with Metformin Monotherapy

Herpes Labialis

A Phase II Study of Repeat Dosing of XXX in Subject with Herpes Labialis

A Phase II, Multi-site, Randomized, Double-blind, Vehicle-controlled Study of the Efficacy and XXX in Subjects with Recurrent Herpes Labialis Single versus Two-dose Arm Application

Hypertension

A Double-blind, Controlled Study to Evaluate the Efficacy and Safety of XXX in Patients with Essential Hypertension

Men's Health

A 12 month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral XXX in Hypogonadal Men

A Phase IIb, Multicenter, Double-blind, Dose-ranging, Randomized, Placebo-controlled Study Evaluating Safety and Efficacy of XXX in Male Obese Subjects with Hypogonadotropic Hypogonadism

INVESTIGATOR EXPERIENCE (*continued*):

Migraine

A Phase II/III, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Multiple Dosing Regimens of Oral XXX in Episodic Migraine Prevention

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Month Subcutaneous Administration of XXX versus Placebo for the Preventive Treatment of Migraine in Patients with Inadequate Response to 2 to 4 Other Preventive Treatments

Nocturia

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center study to Investigate the Efficacy and Safety of XXX in the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia (BMH)

A randomized, double-blind, placebo-controlled, response-adaptive dose-finding trial investigating the efficacy, safety and tolerability of Oral Doses of XXX, with XXX Orally Disintegrating Tablet as a benchmark, during 12 weeks of treatment for Nocturia due to Nocturnal Polyuria in Adults

Psoriasis

A randomized, double-blind, placebo-controlled, multicenter, 24-week study to assess the efficacy and safety of XXX extended release tablets in subjects with Moderate to Severe Plaque Psoriasis

Women's Health

Multi-center, open-label, uncontrolled study to assess contraceptive efficacy and safety of Mirena during extended use beyond 5 years in women 18 to 35 years of age including a subgroup evaluation of treatment effect on heavy menstrual bleeding

Overactive Bladder

An International Phase III, randomized, double-blind, placebo- and active XXX-controlled multicenter study to evaluate the safety and efficacy of XXX in patients with symptoms of Overactive Bladder

A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral XXX in the treatment of Overactive Bladder (OAB) in adult female subjects

INVESTIGATOR EXPERIENCE (*continued*):

Other Indications

A randomized, controlled, double-blind, study of healthy term formula fed (FF) infants. FF infants will be randomized to receive either a new infant formula formulated for healthy term infants (formula B) or a commercially available infant formula for healthy term infants (Formula A). Infants will consume the formula for a total of 16 weeks; infant growth, serum markers of nutritional status, and tolerance to the formulas will be assessed throughout the study.

Clinical Performance of the XXX Mycoplasma Genitalium Assay on the PantherA® System